---
title: "VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296537513.md"
description: "VieMed Healthcare reported record 2025 results, including $270.3M net revenue and $61.4M Adjusted EBITDA, alongside strong first-half 2026 momentum. The company provided 2026 guidance projecting net revenue of $314M–$320M and Adjusted EBITDA of $64M–$68M. VieMed highlighted a debt-free balance sheet, $46M in credit availability, and a new share repurchase program up to 5% of shares. Strategic growth is driven by expansions in sleep, women’s health, and oxygen therapies, supported by an active M&A pipeline and AI operational leverage."
datetime: "2026-08-20T21:13:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296537513.md)
  - [en](https://longbridge.com/en/news/296537513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296537513.md)
generator: "portal-rs"
---

# VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance

**VieMed Healthcare reported record 2025 revenue and Adjusted EBITDA and provided 2026 guidance while sharing an investor presentation highlighting growth, cash generation, and a new buyback program.**

**Key Highlights:**

-   Posted record 2025: $270.3M net revenue, $61.4M Adjusted EBITDA, $28.1M free cash flow.
-   1H 2026 momentum: Q2 revenue $78.1M, Adjusted EBITDA $13.7M, TTM FCF $34M, vent patient census at record 12,635.
-   2026 guidance: Net revenue $314M–$320M, Adjusted EBITDA $64M–$68M, net capex 8.5%–10% of revenue.
-   Balance sheet & capital allocation: effectively no net debt, $46M credit availability, new repurchase program up to 5% of shares.
-   Strategic growth drivers: expansion of sleep, women’s health, oxygen and airway clearance; active M&A pipeline and tech/AI operational leverage.

Original SEC Filing: VIEMED HEALTHCARE, INC. \[ VMD \] - 8-K - Aug. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VMD.US](https://longbridge.com/en/quote/VMD.US.md)

## Related News & Research

- [Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands](https://longbridge.com/en/news/297404631.md)
- [VER: Q2 2026 delivered 6.5% like-for-like revenue growth and strong gross margin, with 2026 guidance reaffirmed](https://longbridge.com/en/news/297124510.md)
- [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md)
- [Systemair corrects dividend record date to Aug. 31, 2026 from Sept. 31 error](https://longbridge.com/en/news/297344953.md)
- [Vuxen Group announces availability of FY2025/2026 annual report (May 1, 2025–April 30, 2026)](https://longbridge.com/en/news/297499193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**